- Poster presentation
- Open Access
Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab
© Koguchi et al. 2015
- Published: 4 November 2015
- Overall Survival
- Metastatic Melanoma
- Quadratic Effect
- Poor Overall Survival
Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumor itself, efficacy may be uniquely sensitive to immunomodulatory factors present at the time of treatment.
We analyzed serum from patients with metastatic melanoma (247 of 273, 90.4%) randomly assigned to receive ipilimumab or gp100 peptide vaccine (NCT00094653). We quantified candidate biomarkers at baseline and assessed the association of each with overall survival using univariate and multivariate analyses. Results were confirmed in an independent cohort of similar patients (48 of 52, 92.3%) treated with ipilimumab (NCT00495066).
Univariate analysis of biomarkers identified chemokine (C-X-C motif) ligand 11 (CXCL11) and soluble MHC class I polypeptide-related chain A (sMICA) as potential predictive biomarkers for ipilimumab but not gp100 therapy for metastatic melanoma. After controlling for baseline covariates, elevated CXCL11 and sMICA were associated with poor OS in ipilimumab-treated patients (log10 CXCL11: hazard ratio (HR), 1.88; 95% CI, 1.14 to 3.12; P = 0.014; and log10 sMICA quadratic effect P = 0.066; sMICA (≥247 vs < 247): HR, 1.75; 95% CI, 1.02 to 3.01) but not in gp100-treated patients. Multivariate analysis of an independent ipilimumab-treated cohort confirmed the association between log10 CXCL11 and OS (HR, 3.18; 95% CI 1.13 to 8.95; P = 0.029), while sMICA was less strongly associated with OS (log10 sMICA quadratic effect P = 0.16; sMICA (≥247 vs < 247): HR, 1.48; 95% CI, 0.67 to 3.27).
Low baseline CXCL11 and sMICA were associated with improved OS in patients with metastatic melanoma after ipilimumab treatment but not vaccine treatment. Thus, pretreatment CXCL11 and sMICA may represent predictors of survival benefit after ipilimumab treatment as well as therapeutic targets. Furthermore, their role in recruiting T regulatory cells (CXCL11) and inhibiting cytolytic effector cells (sMICA) suggests that combination therapies targeting these molecules may synergize with CTLA-4 blockade in patients.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.